Introduction:

sublingual immunotherapy makes its way into allergological practice and numerous studies confirm its effectiveness and safety.

Objective:

to characterize the results with the use of Valergen sublingual vaccines in asthmatic patients of Cabaiguan municipality.

Method:

a descriptive-prospective investigation was conducted from January 2013 to December 2016 in patients diagnosed with intermittent bronchial asthma, persistent, slow and moderate. The universe was constituted by 467 patients. The sample was of 44 patients, of all ages and sexes, who met these conditions, were seen in consultation during the studied period and evaluated each patient after three years of treatment with immunotherapy. The data were obtained from the clinical records and the vaccination record of the allergy department.

Results:

female patients between 5-14 years (34.1%), and Dermatophagoide pteronyssinus was the mite with the highest sensitivity and use (45.4%), after 3 years of treatment, patients with a better control of their symptoms (72.7%), there were no adverse events (79.5%) in the patients, those presented were classified as local and mild systemic (20.5%).

Conclusions:

sublingual immunotherapy for bronchial asthma proved to be safe and clinically favorable in the patients.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )